The US health regulator has provided its approval to Lupin for marketing its Desoximetasone ointment that are used in providing relief from inflammation and itching in a skin disease.

Lupin has said in a BSE filing that the company has received final approval to market its Desoximetasone ointment USP, 0.05 percent from the United States Food & Drug Administration (USFDA).

It added that the product filing is from the company’s Pithampur manufacturing facility.

Read EquityPandit’s Technical Analysis on Nifty Pharma